canakinumab   

GtoPdb Ligand ID: 6773

Synonyms: ACZ 885 | ACZ885 | Ilaris®
canakinumab is an approved drug (FDA (2009), EMA (2009))
Compound class: Antibody
Comment: Canakinumab targets interleukin-1β [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
References
1. Church LD, McDermott MF. (2009)
Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.
Curr. Opin. Mol. Ther., 11 (1): 81-9. [PMID:19169963]
2. Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM. (2018)
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
J. Am. Coll. Cardiol., 71 (21): 2392-2401. [PMID:29544870]
3. Gram H, Di Padova FE. (2008)
Antibodies to human IL-1β.
Patent number: US7446175. Assignee: Novartis Ag. Priority date: 22/08/2000. Publication date: 04/11/2008.
4. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN et al.. (2009)
Use of canakinumab in the cryopyrin-associated periodic syndrome.
N. Engl. J. Med., 360 (23): 2416-25. [PMID:19494217]
5. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD et al.. (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N. Engl. J. Med., 377 (12): 1119-1131. [PMID:28845751]
6. Ridker PM, Lüscher TF. (2014)
Anti-inflammatory therapies for cardiovascular disease.
Eur. Heart J., 35 (27): 1782-91. [PMID:24864079]
7. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, Brik R, McCann L, Kasapcopur O, Rutkowska-Sak L et al.. (2012)
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
N. Engl. J. Med., 367 (25): 2396-406. [PMID:23252526]